TNFSF11 and breast carcinoma: Recently, it was reported that oral administration of AS2676293, a small-molecule inhibitor of RANKL, reduced bone metastasis of breast cancer cells and malignant melanoma by inhibiting not only bone resorption but also RANKL-induced tumor migration in a murine model [113].